123 related articles for article (PubMed ID: 9836286)
21. Long duration of anticoagulant activity and protective effects of acharan sulfate in vivo.
Li DW; Lee IS; Sim JS; Toida T; Linhardt RJ; Kim YS
Thromb Res; 2004; 113(1):67-73. PubMed ID: 15081567
[TBL] [Abstract][Full Text] [Related]
22. Preparation and anticoagulation activity of sodium cellulose sulfate.
Wang ZM; Li L; Zheng BS; Normakhamatov N; Guo SY
Int J Biol Macromol; 2007 Oct; 41(4):376-82. PubMed ID: 17602735
[TBL] [Abstract][Full Text] [Related]
23. Estrogenic effects of 17 beta-aminoestrogens assessed in uteri of rats and mice.
Lemini C; Franco Y; Avila ME; Jaimez R
Eur J Pharmacol; 2005 Mar; 510(3):235-9. PubMed ID: 15763248
[TBL] [Abstract][Full Text] [Related]
24. [State of the blood coagulation system under the experimental action of the anticoagulant bephedon hyperbaric oxygenation and their combination].
Reznikov KM; Trukhacheva LI; Ekimov VA
Probl Gematol Pereliv Krovi; 1981 Nov; 26(11):34-7. PubMed ID: 7323040
[No Abstract] [Full Text] [Related]
25. Anticoagulant activity of Heraclenin.
Mishra KC; Sharma RC; Sharma YN; Arora RB
Indian J Physiol Pharmacol; 1969 Jul; 13(3):153-5. PubMed ID: 5362630
[No Abstract] [Full Text] [Related]
26. Synthesis and anticoagulant activities of substituted 2,4-diketochromans, biscoumarins, and chromanocoumarins.
Manolov I; Maichle-Moessmer C; Nicolova I; Danchev N
Arch Pharm (Weinheim); 2006 Jun; 339(6):319-26. PubMed ID: 16649158
[TBL] [Abstract][Full Text] [Related]
27. Anticoagulant property of a semi-synthesized sodium beta-1,4-glucan sulfate.
Wang ZM; Li L; Li B; Guo SY
Yao Xue Xue Bao; 2006 Apr; 41(4):323-7. PubMed ID: 16856476
[TBL] [Abstract][Full Text] [Related]
28. Oral anticoagulant initiation: rationale for the use of warfarin dosing nomograms.
Crowther MA
Semin Vasc Med; 2003 Aug; 3(3):255-60. PubMed ID: 15199458
[TBL] [Abstract][Full Text] [Related]
29. Construction and functional evaluation of hirudin derivatives with low bleeding risk.
Zhang C; Yu A; Yuan B; Dong C; Yu H; Wang L; Wu C
Thromb Haemost; 2008 Feb; 99(2):324-30. PubMed ID: 18278181
[TBL] [Abstract][Full Text] [Related]
30. The failure of intravenous estrogens (premarin) to affect plasma clotting factors in humans.
KUDISH HG; RAPAPORT SI
Trans West Sect Am Urol Assoc; 1959; 27():53-6. PubMed ID: 14412461
[No Abstract] [Full Text] [Related]
31. The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation--a comparison with other anticoagulants.
Mohri M; Sugimoto E; Sata M; Asano T
Thromb Haemost; 1999 Dec; 82(6):1687-93. PubMed ID: 10613656
[TBL] [Abstract][Full Text] [Related]
32. Pravastatin potentiates the anticoagulant effects of low molecular weight heparin.
Zimmer JE; Spillert CR; Puppala S; Zamecki K; Bhatt BA; Arora RR
Thromb Res; 2004; 113(6):407-10. PubMed ID: 15226096
[TBL] [Abstract][Full Text] [Related]
33. [Effects of estrogens on blood clotting].
Jarzyna A; Wróblewski M
Pol Tyg Lek; 1966 Sep; 21(36):1363-6. PubMed ID: 6009170
[No Abstract] [Full Text] [Related]
34. Amplified anticoagulant activity of tissue factor-targeted thrombomodulin: in-vivo validation of a tissue factor-neutralizing antibody fused to soluble thrombomodulin.
Wang YX; Wu C; Vincelette J; Martin-McNulty B; Alexander S; Larsen B; Light DR; McLean K
Thromb Haemost; 2006 Sep; 96(3):317-24. PubMed ID: 16953273
[TBL] [Abstract][Full Text] [Related]
35. [Coagulative influence of 5-oxo-6-amino-7-ketimino-6-phenyldibenzo(a.c)cycloheptan].
Milosev M; Aleksiev B; Nikolova M; Angelova O
Pharmazie; 1972 Aug; 27(8):520-1. PubMed ID: 5084571
[No Abstract] [Full Text] [Related]
36. [Blood clotting factors following estrogen therapy].
Hochstaedt B; Kahane ES
Harefuah; 1980 Apr; 98(7):295-7. PubMed ID: 7419109
[No Abstract] [Full Text] [Related]
37. Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention.
Marmur JD; Poludasu S; Feit A; Battala VR; Cavusoglu E
J Invasive Cardiol; 2008 Jul; 20(7):323-7. PubMed ID: 18599887
[TBL] [Abstract][Full Text] [Related]
38. Anticoagulant characteristics of HD1-22, a bivalent aptamer that specifically inhibits thrombin and prothrombinase.
Müller J; Freitag D; Mayer G; Pötzsch B
J Thromb Haemost; 2008 Dec; 6(12):2105-12. PubMed ID: 18826387
[TBL] [Abstract][Full Text] [Related]
39. Effect of estrogens on blood clotting.
Jarzyna A; Wróblewski M
Pol Med J; 1967; 6(3):754-9. PubMed ID: 6038099
[No Abstract] [Full Text] [Related]
40. [The pharmacology of estrogens].
Mohr K
Pharm Unserer Zeit; 2004; 33(5):360-4. PubMed ID: 15497330
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
